Scancell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
ScanCell Holdings’ potential DNA cancer vaccine, which is administered via an electrical field-driven device, shows preliminary evidence of efficacy in late-stage melanoma patients.